Andrew W. Harmon

Andrew W. Harmon

Auto-generated profile, based on publicly available information

Andrew W. Harmon

Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2013 in Nature Communications
Verified
Journal Article
Open access
PDF file
HNHaruko Nakano
Haruko Nakano
XLXiaoqian Liu
Xiaoqian Liu
AAArmin Arshi
Armin Arshi
YNYasuhiro Nakashima
Yasuhiro Nakashima
BHBen van Handel
Ben van Handel
ANAtsushi Nakano
Atsushi Nakano
Haematopoietic cells arise from spatiotemporally restricted domains in the developing embryo. Although studies of non-mammalian animal and in vitro embryonic stem cell models suggest a close relationship among cardiac, endocardial and haematopoietic lineages, it remains unknown whether the mammalian heart tube serves as a haemogenic organ akin to the dorsal aorta. Here we examine the haemogenic activity of the developing endocardium. Mouse heart explants generate myeloid and erythroid colonies in the absence of circulation. Haemogenic activity arises from a subset of endocardial cells in the outflow cushion and atria earlier than in the aorta-gonad-mesonephros region, and is transient and definitive in nature. Interestingly, key cardiac transcription factors, Nkx2–5 and Isl1, are expressed in and required for the haemogenic population of the endocardium. Together, these data suggest that a subset of endocardial/endothelial cells serve as a de novo source for transient definitive haematopoietic progenitors.


1 September 2015 in Journal of Molecular and Cellular Cardiology
Verified
Journal Article
Closed access
GLGentian Lluri
Gentian Lluri
VHVincent Huang
Vincent Huang
MTMarlin Touma
Marlin Touma
XLXiaoqian Liu
Xiaoqian Liu
AHAndrew W. Harmon
Andrew W. Harmon
ANAtsushi Nakano
Atsushi Nakano

5 February 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AHAndrew W. Harmon
Andrew W. Harmon
RMRituparna Moitra
Rituparna Moitra
ZXZhili Xu
Zhili Xu
Andrew ByrnesAndrew Byrnes
Andrew Byrnes
Adenovirus vectors are widely used in gene therapy clinical trials, and preclinical studies with these vectors are often conducted in mice. It is therefore critical to understand whether mouse studies adequately predict the behavior of adenovirus vectors in humans. The most commonly-used adenovirus vectors are derived from adenovirus serotype 5 (Ad5). The Ad5 hexon protein can bind coagulation factor X (FX), and binding of FX has a major impact on vector interactions with other blood proteins. In mouse serum, FX protects Ad5 vectors from neutralization by natural antibodies and complement. In the current study, we similarly find that human FX inhibits neutralization of Ad5 vectors by human serum, and this finding is consistent among individual human sera. We show that human IgM and human IgG can each induce complement-mediated neutralization when Ad5 vectors are not protected by FX. Although mouse and human serum had similar effects on Ad5 vectors, we found that this was not true for a chimeric Ad5 vector that incorporated hexon regions from adenovirus serotype 48. Interestingly, this hexon-chimeric vector was neutralized by human serum, but not by mouse serum. These findings indicate that studies in mouse serum accurately predict the behavior of Ad5 vectors in human serum, but mouse serum is not an accurate model system for all adenovirus vectors.

24 May 2017
Verified
Book Chapter
Closed access
PDF file
AHAndrew W. Harmon
Andrew W. Harmon
Andrew ByrnesAndrew Byrnes
Andrew Byrnes

1 July 2017
Verified
Book Chapter
Closed access
PDF file
ZXZhili Xu
Zhili Xu
JTJie Tian
Jie Tian
AHAndrew W. Harmon
Andrew W. Harmon
Andrew ByrnesAndrew Byrnes
Andrew Byrnes